Company intelligence / Profile preview

Rezolute, Inc.

Redwood City, California, United Statesrezolutebio.com ↗

Ownership: Public · RZLT
Employees: ~59
Development stage: Phase 3

Overview

Rezolute is conducting a Phase 3 clinical trial for ersodetug (RZ358), a human monoclonal antibody for the treatment of congenital hyperinsulinism. They also have RZ402, an oral plasma kallikrein inhibitor in Phase 2 clinical trial for diabetic macular edema. Recent publications indicate positive outcomes from an expanded access program for compassionate use of ersodetug for hypoglycemia due to tumor hyperinsulinism[4][5].

Therapeutic areas: OphthalmologyEndocrinology
Modalities: Monoclonal antibodiesOral plasma kallikrein inhibitor
Industry: Biotech

Drug pipeline

5 assets

ersodetug

4 more assets in the full pipeline.

Request access →

Financials

Market cap: $390.9M
Total revenue: $0
Enterprise value: $271.8M

Beyond the preview

Go deeper on Rezolute, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rezolute, Inc..

Explore the full profile